Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Examining anxiety and depression in haematology cancer patients in ongoing treatment and under watchful waiting: A systematic review and meta‐analysis

Examining anxiety and depression in haematology cancer patients in ongoing treatment and under... INTRODUCTIONHaematology cancer (HC) describes any cancer affecting the blood, bone or lymphatic system (NICE, 2016). The term describes over 90 diagnoses, each associated with different characteristics (Blood Cancer UK, 2019). HC accounts for an estimated 5% of cancer cases globally (Sung et al., 2021) and 9% of those diagnosed in high economically developed countries (Smith et al., 2011). Though HC affects individuals across the lifespan, there is a marked increase in incidence in individuals aged 50 years and over (Smith et al., 2011).On average, 50% of people diagnosed with HC in the United Kingdom are expected to survive for 10 years or more, thanks to advances in treatment development (Foster et al., 2018). The move from viewing cancer as an acute life‐threatening illness to a chronic condition means focus has shifted to exploring how individuals can live well alongside their diagnosis (Pitman et al., 2018). Anxiety and depression are commonly diagnosed disorders that can significantly increase the psychosocial burden of living with cancer (Gold et al., 2020). It is estimated that depression affects approximately 20%, and anxiety approximately 10%, of people living with cancer, higher than prevalence rates seen in the general population (Pitman et al., 2018). Psycho‐oncology theories have aimed to explain mechanisms of increased risk of psychological distress http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

Examining anxiety and depression in haematology cancer patients in ongoing treatment and under watchful waiting: A systematic review and meta‐analysis

Loading next page...
 
/lp/wiley/examining-anxiety-and-depression-in-haematology-cancer-patients-in-KEbhY20vtH

References (67)

Publisher
Wiley
Copyright
© 2022 John Wiley & Sons Ltd
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1111/ecc.13678
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONHaematology cancer (HC) describes any cancer affecting the blood, bone or lymphatic system (NICE, 2016). The term describes over 90 diagnoses, each associated with different characteristics (Blood Cancer UK, 2019). HC accounts for an estimated 5% of cancer cases globally (Sung et al., 2021) and 9% of those diagnosed in high economically developed countries (Smith et al., 2011). Though HC affects individuals across the lifespan, there is a marked increase in incidence in individuals aged 50 years and over (Smith et al., 2011).On average, 50% of people diagnosed with HC in the United Kingdom are expected to survive for 10 years or more, thanks to advances in treatment development (Foster et al., 2018). The move from viewing cancer as an acute life‐threatening illness to a chronic condition means focus has shifted to exploring how individuals can live well alongside their diagnosis (Pitman et al., 2018). Anxiety and depression are commonly diagnosed disorders that can significantly increase the psychosocial burden of living with cancer (Gold et al., 2020). It is estimated that depression affects approximately 20%, and anxiety approximately 10%, of people living with cancer, higher than prevalence rates seen in the general population (Pitman et al., 2018). Psycho‐oncology theories have aimed to explain mechanisms of increased risk of psychological distress

Journal

European Journal of Cancer CareWiley

Published: Nov 1, 2022

Keywords: anxiety; cancer; depression; haematology; meta‐analysis; prevalence

There are no references for this article.